Olmetan Tablet 40 mg (Olmesartan Medoxomil)

Adult dose

The recommended starting dose is 10 mg once daily, regardless of meals. If blood pressure is not adequately controlled at this dose, it can be increased to 20 mg once daily. If further reduction in blood pressure is required, the dose may increase up to a maximum of 40 mg once daily. The blood pressure-lowering effect appears within 2 weeks after the start of treatment, with maximum effects observed in approximately 8 weeks. If blood pressure is not controlled with monotherapy, it may be combined with thiazide diuretics such as hydrochlorothiazide. To improve adherence, it is recommended to take it at the same time every day (e.g., in the morning) whenever possible. Patients who may experience intravascular volume depletion (e.g., those receiving diuretics, especially with renal impairment) should start treatment at a lower dose with careful monitoring of their condition. <In the elderly> There is no need to adjust the dose when administering this medication to elderly patients aged 65 years or older. No overall difference in efficacy and safety has been observed between elderly and younger patients, but sensitive reactions may not be excluded in some elderly individuals. <In patients with renal impairment> The maximum dose for patients with mild to moderate renal impairment (creatinine clearance 20-60 mL/min) is 20 mg once daily. <In patients with liver impairment> Patients with mild liver impairment do not require dose adjustment. For moderate liver impairment, the recommended starting dose is 10 mg once daily, which may be increased to a maximum of 20 mg daily. There is no experience in using this medication in patients with severe liver impairment, thus its use is not recommended. <In children> The safety and efficacy in children have not been established.

Child dose

The safety and efficacy in children have not been established.

This medication can cause serious harm or death to the fetus and newborn if taken during the second and third trimesters of pregnancy; therefore, it must be discontinued immediately if pregnancy is confirmed. Those allergic to any components of this medication, pregnant or breastfeeding individuals, those undergoing kidney dialysis, individuals with severe liver dysfunction, and those with biliary obstruction should not take this medication. Additionally, individuals with lactose intolerance or specific genetic conditions should also avoid using this medication. Patients with low blood volume or low sodium may experience hypotension when starting this medication, so their condition should be carefully monitored before administration. If hypotension occurs, appropriate measures should be taken. Patients with impaired kidney function or those who have received a kidney transplant, patients with renovascular hypertension, or patients at risk of hyperkalemia should periodically monitor their kidney function and potassium levels while taking this medication, and adjustments should be made according to the physician’s instructions if necessary. Patients with aortic stenosis, mitral valve stenosis, obstruction, or hypertrophic heart disease should exercise caution when using this medication. This medication can cause dizziness due to its blood pressure-lowering effect, so dangerous activities such as high-altitude work or operating vehicles should be avoided. While on this medication, taking potassium-sparing diuretics or potassium supplements can elevate blood potassium levels, so caution is warranted. Taking it with other antihypertensive medications may increase the blood pressure-lowering effect, so consult a physician. Co-administration with lithium may lead to elevated lithium levels and toxicity, so this combination is not recommended. Using non-steroidal anti-inflammatory drugs concurrently may worsen kidney function, necessitating periodic monitoring of kidney function. Administering this medication to pregnant individuals can result in serious harm to the fetus, so it must not be taken during pregnancy, and if pregnancy is suspected, it should be discontinued immediately. Breastfeeding women should note that this medication can be transmitted through breast milk, and it is advisable to either discontinue breastfeeding or stop taking this medication. The safety and efficacy in children have not yet been established, so children should not take this medication. Elderly patients may have increased concentrations of this medication in their bodies, so care should be exercised when administering it. In cases of overdose, symptoms such as hypotension, palpitations, and bradycardia may occur; seek medical assistance immediately in such instances. No evidence of carcinogenicity or genotoxicity was found with long-term use of this medication; however, rare side effects such as liver dysfunction or vascular edema may occur, so consult healthcare professionals if any unusual symptoms appear.

Serious side effects

Urticaria, severe swelling (edema), angioedema, anaphylactic reaction, severe rash with fever, blisters, skin peeling, pain in oral/ocular mucous membranes, difficulty breathing or shortness of breath, asthma attack, respiratory issues with cough and fever, jaundice (yellowing of skin or eyes), severe systemic lethargy, acute renal failure, elevated serum creatinine, sudden and severe headache, thunderclap headache, seizures, altered consciousness, vision changes

Mild side effects

• Dizziness
• headache
• palpitations
• back pain
• bronchitis
• elevation of creatine phosphokinase
• diarrhea
• hematuria
• hyperglycemia
• hypertriglyceridemia

This medication should be stored in a tightly closed container to protect it from air and moisture. The storage temperature should be maintained between 1°C and 25°C, in a cool place.

Appearance

White oval film-coated tablets

Package unit

30 tablets/bottle, 100 tablets/bottle